Poort S R, Rosendaal F R, Reitsma P H, Bertina R M
Hemostasis and Thrombosis Research Center, Leiden University Hospital, The Netherlands.
Blood. 1996 Nov 15;88(10):3698-703.
We have examined the prothrombin gene as a candidate gene for venous thrombosis in selected patients with a documented familial history of venous thrombophilia. All the exons and the 5'- and 3'-UT region of the prothrombin gene were analyzed by polymerase chain reaction and direct sequencing in 28 probands. Except for known polymorphic sites, no deviations were found in the coding regions and the 5'-UT region. Only one nucleotide change (a G to A transition) at position 20210 was identified in the sequence of the 3'-UT region. Eighteen percent of the patients had the 20210 AG genotype, as compared with 1% of a group of healthy controls (100 subjects). In a population-based case-control study, the 20210 A allele was identified as a common allele (allele frequency, 1.2%; 95% confidence interval, 0.5% to 1.8%), which increased the risk of venous thrombosis almost threefold {odds ratio, 2.8; 95% confidence interval, 1.4 to 5.6}. The risk of thrombosis increased for all ages and both sexes. An association was found between the presence of the 20210 A allele and elevated prothrombin levels. Most individuals (87%) with the 20210 A allele are in the highest quartile of plasma prothrombin levels (> 1.15 U/mL). Elevated prothrombin itself also was found to be a risk factor for venous thrombosis.
我们已将凝血酶原基因作为有静脉血栓形成家族史记录的特定患者静脉血栓形成的候选基因进行了研究。通过聚合酶链反应和直接测序对28名先证者的凝血酶原基因的所有外显子以及5'-和3'-非翻译区进行了分析。除已知的多态性位点外,在编码区和5'-非翻译区未发现偏差。在3'-非翻译区序列中仅鉴定出一个位于20210位的核苷酸变化(从G到A的转换)。18%的患者具有20210AG基因型,而一组健康对照者(100名受试者)中这一比例为1%。在一项基于人群的病例对照研究中,20210A等位基因被确定为常见等位基因(等位基因频率为1.2%;95%置信区间为0.5%至1.8%),其使静脉血栓形成风险增加近三倍(优势比为2.8;95%置信区间为1.4至5.6)。各年龄组和男女的血栓形成风险均增加。发现20210A等位基因的存在与凝血酶原水平升高之间存在关联。大多数具有20210A等位基因的个体(87%)血浆凝血酶原水平处于最高四分位数(>1.15U/mL)。凝血酶原水平升高本身也被发现是静脉血栓形成的一个风险因素。